Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Synovial Sarcoma, X Breakpoint 2 (SSX2)
- Target
- SSX2
- Molecular classification
- Transcription factor, Cancer/Testis Antigen
01
Overview
SSX2 is a transcriptional repressor and a member of the SSX gene family. It is normally expressed in the testis, but aberrantly activated in various cancers, making it a cancer/testis antigen. It is also a key component of the t(X;18) translocation found in synovial sarcomas, forming oncogenic SYT-SSX fusion proteins. Due to its tumor-specific expression and immunogenicity, SSX2 is being investigated as a target for cancer immunotherapy and small molecule inhibitors.
- Other names
- SSX2BCT5.2CT5.2bHOM-MEL-40Synovial sarcoma, X breakpoint 2B
02
Mechanism of action
Not applicable for current drugs. Research focuses on modulating SSX2 function or disrupting SYT-SSX fusion proteins.
03
Biological functions
Transcriptional repressionTranscriptional modulationImmune response regulationChromatin structure modulationGene repression
04
Disease associations
CancerSynovial SarcomaSoft Tissue Sarcoma
05
Safety considerations
Potential for off-target effects due to homology with other SSX family members.Limited normal tissue expression (mainly testis) reduces risk but requires careful consideration.Development of resistance to targeted therapies.
06
Biomarkers
SSX2 expression in tumor tissueSYT-SSX fusion transcript detection
Beyond the preview
Go deeper on Synovial Sarcoma, X Breakpoint 2 (SSX2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synovial Sarcoma, X Breakpoint 2 (SSX2).